Scarica l'app Stockscreener
23.06
4.07%
-1.02
Dopo l'orario di chiusura:
23.50
0.44
+1.91%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$24.08
Aprire:
$24.125
Volume 24 ore:
1.64M
Relative Volume:
1.41
Capitalizzazione di mercato:
$1.33B
Reddito:
$11.13M
Utile/perdita netta:
$-114.59M
Rapporto P/E:
-9.9697
EPS:
-2.313
Flusso di cassa netto:
$-113.96M
1 W Prestazione:
-21.72%
1M Prestazione:
-19.03%
6M Prestazione:
-19.96%
1 anno Prestazione:
+138.14%
Intervallo 1D:
$23.04
$24.25
Intervallo di 1 settimana:
$23.10
$30.93
Portata 52W:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Nome
Capricor Therapeutics Inc
Settore
Industria
Telefono
(310) 358-3200
Indirizzo
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
23.04 | 1.39B | 11.13M | -114.59M | -113.96M | -2.313 |
VRTX
Vertex Pharmaceuticals Inc
|
498.01 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
624.72 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
908.33 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.67 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
187.51 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Iniziato | Alliance Global Partners | Buy |
| 2025-06-26 | Iniziato | B. Riley Securities | Buy |
| 2025-05-20 | Iniziato | Roth Capital | Buy |
| 2024-10-21 | Iniziato | Piper Sandler | Overweight |
| 2024-05-17 | Iniziato | Oppenheimer | Outperform |
| 2024-01-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-26 | Downgrade | Maxim Group | Buy → Hold |
| 2018-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-13 | Ripresa | Rodman & Renshaw | Buy |
| 2016-07-06 | Ripresa | H.C. Wainwright | Buy |
| 2016-06-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
Capricor Therapeutics, Inc. Financial Disclosures & Filings - TradingView
Capricor’s positive 5-year data for DMD treatment comes with a regulatory catch – CAPR stock slides 11% - MSN
July meeting date set for FDA, developer to talk deramiocel for DMD - Muscular Dystrophy News
CAPR Stock Hits Over 4-Month Low: Capricor Execs Cash In $1.5M As FDA Sets Stage For DMD Drug Review - Stocktwits
Securities Class Action Lawsuit Filed Against Capricor Therapeuti - The National Law Review
Capricor CFO Bergmann sells $732k in shares By Investing.com - Investing.com Australia
Capricor Therapeutics EVP Karen Krasney sells $732,158 in stock By Investing.com - Investing.com Australia
Form 4 Capricor Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
Capricor (NASDAQ: CAPR) EVP exercises options and sells 24,100 shares under 10b5-1 plan - Stock Titan
Capricor (NASDAQ: CAPR) CFO sells 24,100 shares under 10b5-1 plan - Stock Titan
Capricor Therapeutics Insiders Sold Shares Worth Over $1.5M - TradingView
CAPR Stock Draws Investor Attention After AAN Presentation For DMD Therapy - Stocktwits
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits
Capricor Therapeutics, Inc.(NasdaqGS: CAPR) dropped from Russell 3000E Index - marketscreener.com
Capricor Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Capricor Therapeutics, Inc.(NasdaqGS:CAPR) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Shareholders of Capricor Therapeutics, Inc. (CAPR): Protect Your - The National Law Review
Capricor Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Litvack Frank - Moomoo
Capricor Therapeutics, Inc.(NasdaqGS: CAPR) dropped from Russell Microcap Index - marketscreener.com
CAPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Lost Money on Capricor Therapeutics, Inc. (CAPR)? Contact Levi - The National Law Review
CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
CAPR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Did You Lose Money on Capricor Therapeutics, Inc. (CAPR)? Levi - The National Law Review
CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
CAPR Stock Surged 17% Today — What’s Fueling The Rally? - Stocktwits
Capricor falls as FDA sets up AdCom meeting to review Duchenne therapy - MSN
Class Action Alert: Levi & Korsinsky Reminds Capricor (CAPR) Investors of September 15, 2025 Deadline - The National Law Review
Levi & Korsinsky Notifies Capricor Therapeutics, Inc. (CAPR) Shar - The National Law Review
CAPR ALERT: Levi & Korsinsky Files Securities Fraud Class Action - The National Law Review
CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision - Stocktwits
Capricor Therapeutics Faces Stock Drop Ahead of FDA Advisory Meeting - Intellectia AI
Capricor Therapeutics Announces FDA Advisory Committee Meeting for Deramiocel Cell Therapy in Duchenne Muscular Dystrophy – Minichart - Minichart
Capricor Therapeutics to Face FDA Advisory Panel on BLA for Deramiocel; PDUFA Aug 22 - TradingView
[8-K] CAPRICOR THERAPEUTICS, INC. Reports Material Event - Stock Titan
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
What's Going On With Capricor Therapeutics Stock On Friday? - Benzinga
Capricor Therapeutics (CAPR) Reports Positive Long-Term Data for Deramiocel - GuruFocus
Capricor’s Positive 5-Year Data For DMD Treatment Comes With A Regulatory Catch – CAPR Stock Slides 11% - Stocktwits
Capricor Therapeutics, Inc. (CAPR) Stock: July FDA Review Tests Deramiocel Outlook - parameter.io
Capricor Therapeutics (CAPR) Faces 12% Decline Ahead of FDA Advi - GuruFocus
Capricor Therapeutics (CAPR) Seeks FDA Meeting for Cell Therapy Approval - GuruFocus
What is the latest on Capricor Therapeutics' Deramiocel and its FDA journey - Kavout | AI
FDA schedules advisory meeting for Capricor’s DMD therapy By Investing.com - Investing.com India
Capricor Therapeutics Says Deramiocel BLA PDUFA Target Action Date Set For August 22 - TradingView
Capricor Therapeutics Announces FDA Advisory Committee - GlobeNewswire
FDA panel to review Capricor’s Duchenne drug on July 29 - Stock Titan
Capricor faces FDA AdCom panel for Duchenne drug (CAPR:NASDAQ) - Seeking Alpha
Capricor reports five-year data for Duchenne therapy deramiocel By Investing.com - Investing.com Canada
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference - The Manila Times
Capricor Therapeutics Inc Azioni (CAPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.99%
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):